Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1651 to 1665 of 8938 results

  1. Naloxegol for treating opioid‑induced constipation (TA345)

    Evidence-based recommendations on naloxegol (Moventig) for treating opioid-induced constipation in adults.

    Technology appraisal guidance
    Published
    22 July 2015
    View recommendations

    Sections for TA345

  2. Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab (TA612)

    Evidence-based recommendations on neratinib (Nerlynx) for extended adjuvant treatment of hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-positive early stage breast cancer in adults.

    Technology appraisal guidance
    Published
    20 November 2019
    View recommendations

    Sections for TA612

  3. Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes (TA583)

    Evidence-based recommendations on ertugliflozin (Steglatro) with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes in adults.

    Technology appraisal guidance
    Published
    5 June 2019
    View recommendations

    Sections for TA583

  4. Tabelecleucel for treating post-transplant lymphoproliferative disorder caused by the Epstein-Barr virus (terminated appraisal) (TA923)

    NICE is unable to make a recommendation on tabelecleucel (Ebvallo) for treating post-transplant lymphoproliferative disorder caused by the Epstein-Barr virus. This is because Pierre Fabre Ltd did not provide an evidence submission. We will review this decision if the company decides to make a submission.

    Technology appraisal guidance
    Published
    19 October 2023

    Sections for TA923

  5. Transvenous embolisation for treating cerebrospinal fluid-venous fistula associated with spontaneous intracranial hypotension

    In development Reference number: GID-IPG10318 Expected publication date:  25 March 2026

    Interventional procedures guidance
    In development

  6. Suspected Cancer: recognition and referral (update)

    In development Reference number: GID-NG10443 Expected publication date:  25 March 2026

    NICE guideline
    In development

  7. Percutaneous insertion of a catheter-based left ventricular microaxial flow pump for cardiogenic shock

    In development Reference number: GID-IPG10404 Expected publication date:  25 March 2026

    Interventional procedures guidance
    In development

  8. Surgical insertion of a catheter-based left ventricular microaxial flow pump for cardiogenic shock

    In development Reference number: GID-IPG10461 Expected publication date:  25 March 2026

    Interventional procedures guidance
    In development

  9. Transcatheter Tricuspid Valve Replacement

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  10. Spinal instrumentation with robot assisted navigation

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  11. Oesophageal String Test

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  12. RenalGuard Therapy for reduction in the incidence of Contrast-Associated AKI (CA-AKI) in at-risk patients

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  13. Lymphatico-venous anastomosis for chronic lymphoedema

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  14. High linear energy transfer radiation for carbon ion beam therapy

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  15. Fetoscopic tracheal occlusion (FETO) for severe congenital diaphragmatic hernia

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation